effectiveness of milagu legium for virana silethumam (acute pharyngo-tonsilitis) in children.
Phase 2
Completed
- Conditions
- Health Condition 1: J039- Acute tonsillitis, unspecified
- Registration Number
- CTRI/2022/07/043678
- Lead Sponsor
- ational Institute of Siddha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1.Children aged 5 to 12 years
2.Both Male and Female
3.Throat pain
4.Mild fever
5.Enlarged tonsils
Exclusion Criteria
1.Pneumonia
2.Oral candidiasis
3.Primary complex
4.Congenital cardiac disease
5.Peritonsillar abscess
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of the drug will be assessed by reduction of clinical symptomsTimepoint: Efficacy of the drug will be assessed by reduction of clinical symptoms within 14 days
- Secondary Outcome Measures
Name Time Method ilTimepoint: Nil
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of Milagu legium in treating acute pharyngo-tonsillitis in children?
How does Milagu legium compare to standard-of-care antibiotics for acute tonsillitis in pediatric patients?
Are there specific biomarkers that can predict response to Milagu legium in children with acute pharyngo-tonsillitis?
What are the potential adverse events associated with Milagu legium treatment in children and how are they managed?
What other Siddha formulations or compounds are being studied for pharyngo-tonsillitis alongside Milagu legium?